A significant number of Phase 2 participants achieved clinically meaningful weight loss at 4mg and 8mg
Judge Pratter had played an active role in the Ozempic lawsuit, which is now in a brief hiatus as plaintiffs and defendants await the appointment of a new judge by the Judicial Panel on Multidistrict litigation
Retatrutide (LY3437943) is blowing up both the pharmaceutical world and the bodybuilding world for the same reason: This triple G multi-receptor agonist manufactured by pharmaceutical company Eli Lilly has paved the way for what could be an entirely new generation of anti-obesity drugs
If the research interest is in an earlier-stage dual agonist to compare against more established compounds, survodutide provides a useful contrast point, with the caveat that its data set is still developing
Sharma N, et al
In a phase 2 clinical trial targeting obese individuals without type 2 diabetes (T2D), retatrutide dosed at 1 to 12 mg resulted in up to 24.2% weight loss over a 48-week treatment period, compared to 2.1% in the placebo group, and demonstrated a dose-dependent effect
